Search results
Showing 196 to 210 of 1286 results for long term conditions
Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.
Show all sections
Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)
Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.
E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (MTG16)
Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.
This quality standard covers admissions into, and discharge from, inpatient hospital settings for adults (aged 18 years and over) with social care needs. It describes high-quality care in priority areas for improvement.
View quality statements for QS136Show all sections
Sections for QS136
- Quality statements
- Quality statement 1: Information sharing on admission
- Quality statement 2: Comprehensive geriatric assessment
- Quality statement 3: Coordinated discharge
- Quality statement 4: Discharge plans
- Quality statement 5: Involving carers in discharge planning
- Update information
- About this quality standard
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)
This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.
People's experience using adult social care services (QS182)
This quality standard covers the experience of adults using social care services. It applies to all settings where people use social care services, including people's own homes, residential care and community settings. Its aim is to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care. It describes high-quality care in priority areas for improvement.
View quality statements for QS182Show all sections
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.
This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over (TA1031)
Evidence-based recommendations on vamorolone (Agamree) for treating Duchenne muscular dystrophy in people 4 years and over.
Show all sections
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.
Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.